Anbio Biotechnology Class A Ordinary Shares (NNNN) EBITDA: History & Chart

Anbio Biotechnology Class A Ordinary Shares(NNNN)

Medical - Instruments & Supplies · Frankfurt am Main, HE

$4.94+0.11 (+2.28%)

Delayed quote: Oct 6, 2026, 1:53 PM EDT

About Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.

Frankfurt am Main, HE

27 employees

www.anbio.com

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Michael Lau

View full financials

Period	EBITDA	QoQ Growth	YoY Growth
Q4 FY2025Period end 2025-12-31	$2.80M	N/A	N/A
Q2 FY2025Period end 2025-06-30	$3.68M	N/A	N/A
Q4 FY2024Period end 2024-12-31	−$1.74M	N/A	N/A
Q2 FY2024Period end 2024-06-30	$3.89M	N/A	N/A
Q4 FY2023Period end 2023-12-31	$587.28K	N/A	N/A
Q2 FY2023Period end 2023-06-30	$1.55M	N/A	N/A

EBITDA

NNNN EBITDA

Current EBITDA

QoQ Growth

Historical Data

Quarterly EBITDA History

Related Metrics